155 related articles for article (PubMed ID: 12435777)
1. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.
Heath KV; Chan KJ; Singer J; O'Shaughnessy MV; Montaner JS; Hogg RS
Int J Epidemiol; 2002 Oct; 31(5):1016-20. PubMed ID: 12435777
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.
Heath KV; Hogg RS; Singer J; Chan KJ; O'Shaughnessy MV; Montaner JS
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):440-7. PubMed ID: 12138351
[TBL] [Abstract][Full Text] [Related]
3. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.
Heath KV; Hogg RS; Chan KJ; Harris M; Montessori V; O'Shaughnessy MV; Montanera JS
AIDS; 2001 Jan; 15(2):231-9. PubMed ID: 11216932
[TBL] [Abstract][Full Text] [Related]
4. Adipocytokine dysregulation, abnormal glucose metabolism, and lipodystrophy in HIV-infected adolescents receiving protease inhibitors.
Santiprabhob J; Chokephaibulkit K; Khantee P; Maleesatharn A; Phonrat B; Phongsamart W; Lapphra K; Wittawatmongkol O; Rungmaitree S; Tanchaweng S; Maturapat S; Lermankul W; Tungtrongchitr R
Cytokine; 2020 Dec; 136():155145. PubMed ID: 32920318
[TBL] [Abstract][Full Text] [Related]
5. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
[TBL] [Abstract][Full Text] [Related]
6. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.
Miller J; Carr A; Emery S; Law M; Mallal S; Baker D; Smith D; Kaldor J; Cooper DA
HIV Med; 2003 Jul; 4(3):293-301. PubMed ID: 12859330
[TBL] [Abstract][Full Text] [Related]
7. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
Martinez E; Mocroft A; García-Viejo MA; Pérez-Cuevas JB; Blanco JL; Mallolas J; Bianchi L; Conget I; Blanch J; Phillips A; Gatell JM
Lancet; 2001 Feb; 357(9256):592-8. PubMed ID: 11558485
[TBL] [Abstract][Full Text] [Related]
8. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.
Tsiodras S; Mantzoros C; Hammer S; Samore M
Arch Intern Med; 2000 Jul; 160(13):2050-6. PubMed ID: 10888979
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Feleke Y; Fekade D; Mezegebu Y
Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
[TBL] [Abstract][Full Text] [Related]
10. Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed.
Sarni RO; Souza FI; Battistini TR; Pitta TS; Fernandes AP; Tardini PC; Fonseca FL; Dos Santos VP; Lopez FA
J Pediatr (Rio J); 2009; 85(4):329-34. PubMed ID: 19668909
[TBL] [Abstract][Full Text] [Related]
11. Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.
Bhutia E; Hemal A; Yadav TP; Ramesh KL
Afr Health Sci; 2014 Jun; 14(2):408-13. PubMed ID: 25320591
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
[TBL] [Abstract][Full Text] [Related]
13. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.
Piloya T; Bakeera-Kitaka S; Kekitiinwa A; Kamya MR
J Int AIDS Soc; 2012 Jul; 15(2):17427. PubMed ID: 22814353
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
15. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.
Galli M; Cozzi-Lepri A; Ridolfo AL; Gervasoni C; Ravasio L; Corsico L; Gianelli E; Vaccarezza M; Vullo V; Cargnel A; Minoli L; Coronado O; Giacometti A; Antinori A; Antonucci G; D'Arminio Monforte A; Moroni M;
Arch Intern Med; 2002 Dec 9-23; 162(22):2621-8. PubMed ID: 12456235
[TBL] [Abstract][Full Text] [Related]
16. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
[TBL] [Abstract][Full Text] [Related]
17. Anthropometric definitions for antiretroviral-associated lipodystrophy derived from a longitudinal South African cohort with serial dual-energy X-ray absorptiometry measurements.
Abrahams Z; Maartens G; Levitt N; Dave J
Int J STD AIDS; 2018 Oct; 29(12):1194-1203. PubMed ID: 29945538
[TBL] [Abstract][Full Text] [Related]
18. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.
Hartman K; Verweel G; de Groot R; Hartwig NG
Pediatr Infect Dis J; 2006 May; 25(5):427-31. PubMed ID: 16645507
[TBL] [Abstract][Full Text] [Related]
19. Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy.
Kratz M; Purnell JQ; Breen PA; Thomas KK; Utzschneider KM; Carr DB; Kahn SE; Hughes JP; Rutledge EA; Van Yserloo B; Yukawa M; Weigle DS
J Clin Endocrinol Metab; 2008 Mar; 93(3):959-66. PubMed ID: 18089690
[TBL] [Abstract][Full Text] [Related]
20. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
